Document Detail


Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity.
MedLine Citation:
PMID:  17335544     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: To examine retrospectively the relationship between DPD phenotype/genotype and the intensity of 5FU toxicity. METHODS: One hundred and thirty-one case-reports (81 women, 50 men) with 5FU-related toxicity were analyzed. RESULTS: The lower the DPD activity (10-504 pmol min(-1) mg(-1)), the higher the toxicity grade was scored (P < 0.01). Toxicity-related deaths occurred in nine patients (eight women) who significantly expressed lower DPD activity than other patients. Two of the deceased patients had normal DPD activity. The IVS14+1G>A mutation, analyzed in 93 patients, was detected in two patients (nonlethal toxicity). CONCLUSIONS: The IVS14+1G>A mutation may not help prevent toxicity and patients with normal DPD activity may develop life-threatening 5FU toxicity.
Authors:
Nicolas Magné; Marie-Christine Etienne-Grimaldi; Laurent Cals; Nicole Renée; Jean-Louis Formento; Mireille Francoual; Gérard Milano
Related Documents :
18786134 - Anderson's disease (chylomicron retention disease): a new mutation in the sara2 gene as...
10958764 - Positive influence of the delta32ccr5 allele on response to highly active antiretrovira...
22832674 - A novel assessment of the temporal variation in the fractionated electrograms using a h...
12707074 - Evidence of oxidative stress in familial amyloidotic polyneuropathy type 1.
21829014 - Is extracellular volume expansion of peritoneal dialysis patients associated with great...
20560844 - Small intestine bacterial overgrowth does not correspond to intestinal inflammation in ...
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2007-03-01
Journal Detail:
Title:  British journal of clinical pharmacology     Volume:  64     ISSN:  0306-5251     ISO Abbreviation:  Br J Clin Pharmacol     Publication Date:  2007 Aug 
Date Detail:
Created Date:  2007-07-19     Completed Date:  2007-12-12     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  7503323     Medline TA:  Br J Clin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  237-40     Citation Subset:  IM    
Affiliation:
Institut Gustave Roussy, Villejuif, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic / adverse effects*
Antineoplastic Agents / administration & dosage*,  adverse effects
Dihydrouracil Dehydrogenase (NADP) / administration & dosage*,  adverse effects
Female
Fluorouracil / adverse effects*
Humans
Male
Middle Aged
Mutation, Missense / drug effects*
Polymorphism, Genetic
Chemical
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 0/Antineoplastic Agents; 51-21-8/Fluorouracil; EC 1.3.1.2/Dihydrouracil Dehydrogenase (NADP)
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis...
Next Document:  Age dependent systemic exposure to inhaled salbutamol.